Palvella Therapeutics Inc (PVLA) - News Archive

Showing 3 of 3 results.

Revolutionizing Treatment for Venous Malformations Palvella Therapeutics Pioneers Rapamycin Advances in New R...

In a groundbreaking press release, Palvella Therapeutics has announced significant progress in understanding the pathogenesis of venous malformations, also detailing the systemic off-label use of rapamycin as a targeted...

Sep 17, 2025 • Major Pharmaceutical Preparations Industry Product Service News Price Target

Expansion of Phase 3 SELVA Trial for QTORIN Rapamycin 3.9% Anhydrous Gel in Treating Microcystic Lymphatic Malformati...

In an exciting development for pediatric dermatology, Palvella Therapeutics has announced that its investigational therapy, QTORIN Rapamycin 3.9% anhydrous gel, is making strides toward addressing microcystic lymphatic...

Apr 11, 2025 • Major Pharmaceutical Preparations Industry Product Service News April Palvella Therapeutics April Palvella Therape

Palvella Therapeutics Soars: Closing of Merger with Pieris Pharmaceuticals and $78.9 Million Placement Signals Bright Future for Rare Disease Solutions,

Palvella Therapeutics: A New Dawn for Rare Disease BiopharmaceuticalsIn a significant development for the biopharmaceutical landscape, Palvella Therapeutics is poised to make its mark on the Nasdaq, debuting under the t...

Dec 13, 2024 Merger and Acquisition Merger